RxDoctor Payments Data

Julia Boland, MD

Hospitalist · Los Angeles, CANPI 1922637891

Payments from drug & device makers

$768in general payments, 2019–2025

Across 15 payments — averaging $51.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$232
  • Astellas Pharma US Inc$100
  • Sobi, Inc$100
  • Incyte Corporation$84
  • AstraZeneca$76
  • Eisai Inc.$49
  • plus $127 from 5 others

What the payments were for

  • Food & beverage$48463%
  • Education$28437%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$768 in reported general payments places this provider in the 85th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$169,940
Medicare patients
406
Services billed
1,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$33,878
MyrbetriqMirabegron27$5,872
Pantoprazole Sodium24$1,616
Atorvastatin Calcium42$486
Gabapentin61$441
Nifedipine ErNifedipine28$359
Mirtazapine15$215
Oxycodone Hcl26$192
Amlodipine Besylate26$191
Levetiracetam11$181
Ondansetron OdtOndansetron17$163
Levothyroxine Sodium14$162
Metformin Hcl20$161
ClopidogrelClopidogrel Bisulfate14$134
Warfarin Sodium20$133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$5,87227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →